![Karin Nord](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Karin Nord
Fundador en Affibody Medical AB .
Relaciones activas
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Carl Erik Mathias Uhlén | M | 70 |
Affibody Medical AB
![]() Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | 26 años |
Joachim Feldwisch | M | - |
Affibody Medical AB
![]() Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | - |
Jose F. Suarez | M | 54 |
Affibody Medical AB
![]() Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | - |
J. Kenneth Charles Knowles | M | 77 |
Affibody Medical AB
![]() Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | - |
Robert Forbes Burns | M | 77 |
Affibody Medical AB
![]() Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | - |
Stig Anders Lindberg | M | 52 |
Affibody Medical AB
![]() Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | - |
Anders Martin-Löf | M | 53 |
Affibody Medical AB
![]() Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | 3 años |
David Bejker | M | 49 |
Affibody Medical AB
![]() Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | 6 años |
Per Stefan Andersson-Engels | M | 64 |
Royal Institute of Technology
| 28 años |
Camilla Soenderby | F | - |
Affibody Medical AB
![]() Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | - |
Gráfico relacional
Relaciones con varias empresas
Antiguas relaciones
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Johannes Celander | M | - |
Royal Institute of Technology
| 5 años |
Erik Walldén | M | 75 |
Affibody Medical AB
![]() Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | 2 años |
Jan Ulf Sigvar J. Johansson | M | 79 |
Royal Institute of Technology
| 5 años |
Marcus Lannerbro | M | 49 |
Royal Institute of Technology
| 1 años |
Johan Pejnefors | M | - |
Royal Institute of Technology
| 2 años |
Anders Mattias Letmark | M | 45 |
Royal Institute of Technology
| 5 años |
Johan Conradsson | M | - |
Royal Institute of Technology
| 5 años |
Mats Danielsson | M | 59 |
Royal Institute of Technology
| 3 años |
Pontus Boman | M | 53 |
Royal Institute of Technology
| 4 años |
Daniel Karlgren | M | - |
Royal Institute of Technology
| 1 años |
Anton Lundqvist | M | 54 |
Royal Institute of Technology
| 3 años |
Pasi Juhani Tolppanen | M | 57 |
Royal Institute of Technology
| 3 años |
Peter Wall | M | 52 |
Royal Institute of Technology
| 4 años |
Henrik Von Schoultz | M | - |
Royal Institute of Technology
| 12 años |
Eva Nahari | F | - |
Royal Institute of Technology
| 5 años |
Tuva Berg | F | - |
Royal Institute of Technology
| 12 años |
Rickard Waldenlind | M | - |
Royal Institute of Technology
| 7 años |
Carl-Johan Zetterberg Boudrie | M | 45 |
Royal Institute of Technology
| 5 años |
Fredric Kastevik | M | 50 |
Royal Institute of Technology
| 1 años |
Carl Henrik Gustaf Thane | M | - |
Royal Institute of Technology
| 3 años |
Hans Lennart Rudolf Wigzell | M | 86 |
Affibody Medical AB
![]() Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | - |
Håkan Åström | M | 77 |
Affibody Medical AB
![]() Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | - |
Per Ake Nygren | M | - |
Affibody Medical AB
![]() Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | - |
Karin Hansson | M | 61 |
Royal Institute of Technology
| 3 años |
Carl Jöran Fredrik Cassel | M | 51 |
Royal Institute of Technology
| 5 años |
John Mikael Holtz Elvesjö | M | 47 |
Royal Institute of Technology
| 2 años |
Anders Lundblad | M | - |
Royal Institute of Technology
| 3 años |
Philip Axel Wilhelm Siberg | M | 51 |
Royal Institute of Technology
| 1 años |
Mattias Feiff | M | 52 |
Royal Institute of Technology
| 4 años |
Magnus Lagerström | M | 51 |
Royal Institute of Technology
| 4 años |
Jan Peter Enoksson | M | 67 |
Royal Institute of Technology
| 3 años |
Fredrik Frejd | M | - |
Affibody Medical AB
![]() Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | - |
Fredrik Ramén | M | - |
Royal Institute of Technology
| 4 años |
Hans Lundhagen | M | 52 |
Royal Institute of Technology
| 1 años |
Daniel Wroblewski | M | - |
Royal Institute of Technology
| 4 años |
Estadísticas
País | Relaciones | % del total |
---|---|---|
Suecia | 45 | 100.00% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Karin Nord
- Red Personal